Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

YM BioSciences Reports CYT387 Phase I/II Results Selected by ASH Program Committee

Published: Friday, October 12, 2012
Last Updated: Friday, October 12, 2012
Bookmark and Share
Phase I/II results selected for oral presentation at ASH2012 conference.

YM BioSciences Inc. has announced that the results of its Phase I/II Study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, have been selected by the ASH Program Committee for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology to be held in Atlanta, Georgia on December 9, 2012.

"CYT387 could prove to be an important and differentiated therapeutic for patients with myelofibrosis; the interim data we have reported to date have been highly encouraging," said Dr. Nick Glover, President and CEO of YM BioSciences.

Dr. Glover continued, "We look forward to the release of final nine-month data from the Phase I/II CYT387 study at ASH, as well as further ongoing data from the many patients who continue to benefit from the drug in its Extension trial."

Title: Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Session Name: 634. Myeloproliferative Syndromes - Clinical: Myeloproliferative Neoplasms - Novel Therapies I

Session Date:  Sunday, December 9, 2012; 4:30 PM - 6:00 PM (Presentation Time:  5:15 PM)

Location:  Georgia World Congress Center, Room B213-B214


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 at ASH 2012
68% transfusion independence response rate and 37% durable spleen response rate.
Tuesday, December 11, 2012
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013
Company prepared for pivotal trials with CYT387 during the quarter.
Monday, November 12, 2012
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
Pivotal trials for CYT387 in myelofibrosis to begin in the second half of calendar 2012.
Tuesday, May 15, 2012
YM BioSciences Reports Operational and Financial Results
Company reports operational and financial results for the second quarter of fiscal 2012.
Friday, February 10, 2012
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported.
Tuesday, December 13, 2011
YM BioSciences Nimotuzumab Results Reported at SIOP Conference
Phase II study of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma.
Tuesday, November 01, 2011
YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
Enrollment of phase I/II trial for CYT387 complete.
Monday, September 26, 2011
YM BioSciences Reports Interim Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASCO
Favorable safety and durable efficacy responses recorded.
Thursday, September 01, 2011
YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387
Poster with broader update of trial results to be presented at ASCO.
Thursday, May 19, 2011
YM BioSciences Reports Fiscal Third Quarter 2011 Operational and Financial Results
Operational and financial results for the third quarter of fiscal 2011, ended March 31, 2011.
Thursday, May 12, 2011
YM BioSciences Reports Positive Updated Anemia Response Data for its JAK1/JAK2 Inhibitor CYT387
Results disclosed at First Annual Florence Meeting on Myeloproliferative Neoplasms in Florence, Italy.
Tuesday, April 19, 2011
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial
YM BioSciences Inc., a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, have announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.
Friday, January 21, 2011
YM BioSciences Reports Positive Interim Data from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Results including substantial Anemia response presented at the 52nd American Society of Hematology Annual meeting.
Tuesday, December 07, 2010
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
The Phase I/II clinical trial in patients with myelofibrosis has been expanded to five sites.
Friday, November 19, 2010
YM BioSciences to Present Poster on CYT387 at the European School of Haematology International Conference
CYT387 possesses an excellent enzymatic potency and selectivity profile which may provide significant clinical advantages.
Monday, October 04, 2010
Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!